Stanford Medicine's Ji Research Group has developed a simple, quantitative method for detecting and characterizing gene fusions that uses DNA rather than RNA as analyte.
Stanford scientists have created a de novo protein design platform that designs binding proteins that specifically target antigens in the major histocompatibility complex (MHC).
Running chemotherapeutic drug screens on tumor biopsies ex vivo has the potential to increase patient survival by personally matching them to the drug which is the most effective against their particular tumor.